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the OriGin OF pSychOpharMacOlOGy
Psychopharmacology combines two terms, psychology and pharmacology describing how 
biologically active compounds including drugs regulate psychobiological processes and affect 
behaviors. Reinhard Lorichius originated the term in 1548 in his “Psychopharmakon, hoc est 
medicina animae” a collection of prayers in which the term “psychopharmakon” relates to a spir-
itual medicine to alleviate affliction and miserable situations of life (1, 2). Foundations of modern 
psychopharmacology appear in the nineteenth century with the discovery of chemical agents, such 
as morphine, bromide salts, chloral hydrate, and other general anesthetics. A few decades later, 
the psychostimulant cocaine and depressant barbiturates were identified. During the first half of 
the twentieth century hallucinogenic compounds such as mescaline and LSD, and psychoactive 
amphetamines were also discovered (2–5).
the MaGic yearS OF pSychOpharMacOlOGy
The major breakthrough in the field came between 1950 and 1960 with the discovery of the first 
antipsychotic chlorpromazine, followed by MAO inhibitors and tricyclic antidepressants and a 
few years later by the first benzodiazepine, chlordiazepoxide. Over the next two to three decades, 
the field flourished and psychopharmacology became an extremely popular research area upon 
which interests of pharmacologists, psychiatrists, and psychologists converged. With further 
development in the field, the possibility of treating psychiatric conditions improved enormously, 
and clinical practices in psychiatry were revolutionized. The two major therapies at the time used 
to treat schizophrenia and affective disorders, insulin-induced hypoglycemic coma, and electro-
convulsive shock were replaced by antipsychotic and antidepressant drugs. Agitation and violence 
often tackled with seclusion and restraint were successfully treated with barbiturates and later with 
benzodiazepines (3, 5, 6).
With the discovery of new molecules and mechanisms of drug actions, more sophisticated, 
pharmacocentric based, psychobiological theories emerged to explain psychiatric illness or to 
explain complex behaviors paving the way for modern psychopharmacology.
MOdern pSychOpharMacOlOGy
Over the last three decades, few major scientific breakthroughs dramatically changed the field. 
The advent of new molecular technologies affected major research areas in biomedical sciences 
including psychopharmacology. New potent tools appeared enabling enquiry into the mechanisms 
of diseases. New hypotheses based on molecular information challenged the pharmacocentric 
approach used in psychiatry to determine the causes of specific disorders. At the beginning of the 
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1980s, gene targeting approaches arose allowing the possibility 
of selectively introducing or deleting genes in model animals, 
offering new methods to explore the genetic basis of psychiatric 
illness (7–11). Continued development over the years occurred 
via gene-targeting approaches. Recombinase-based techniques 
allowed the generation of cell/tissue/brain regions for specific 
knockout and knockin mouse lines, offering unprecedented 
possibility to explore brain functions (10). The recent introduc-
tion of CRISPR-Cas-based techniques now makes gene editing 
easier, potentially allowing genome editing at multiple sites 
not only in model animals but also in other species, including 
humans (12–14).
During early 2000s, the human genome was sequenced 
bringing new expectations of deciphering the genetic basis of 
mental illness (15, 16). Psychiatry was revolutionized again by 
the development of high-throughput genotyping platforms 
permitting genetic association studies and identifying genetic 
risk factors for psychiatric disorders (17, 18). Psychiatry genetics 
and genome-wide association studies could help to identify new 
drug targets and potentially new pharmacotreatments for brain 
disorders (19).
The development of epigenetics represents a third important 
breakthrough (20). For decades, the “nature vs nurture” debate 
played a significant role in behavioral sciences particularly in 
the field of psychiatry and psychopharmacology. If on the one 
hand preclinical and clinical research demonstrated that the 
presence of specific genetic traits contributes to the development 
of affective disorders and psychiatric conditions. On the other 
hand, it was also clear that the process of actually developing the 
disease was influenced by a number of other elements generically 
defined as “environmental factors.” Such factors include stress, life 
style, education, individual experiences, and several more (21). 
With the development of epigenetics, the “nature vs nurture” 
dichotomy is dissipating. It is now clear that the environment can 
influence the expression of genetic traits and that genome and 
epigenome interact with each other to shape endophenotypes (21, 
22). Despite genetic vulnerability, the environment influences the 
propensity to develop a disease. On the other hand, genetically 
non-vulnerable subjects, if exposed to particularly detrimental 
environments or to certain individual experiences can develop 
psychiatric pathologies.
Optogenetics and chemogenetics are two other recent inno-
vations heavily influencing the field of psychopharmacology 
(23–26). These new methods allow the insertion of light or drug-
sensitive artificial receptors into specific subset of neurons (27). 
These new approaches, combined with brain imaging techniques, 
electrophysiology, and pharmacology, allow unprecedented pos-
sibilities to explore neuronal circuitry, cytoarchitectures, and 
functions. Optical control of specific cell type on a millisecond 
timescale during animal behavior helps to decipher the contribu-
tion of specific neuronal circuitry and cellular mechanisms in 
the organization of emotional states, cognitive processes, and 
complex behaviors in general. For instance, optogenetics utilized 
in vivo helps unravel physiological mechanisms associated with 
specific forms of learning and memory, motivation and reward, in 
conjunction with the regulation of the sleep-wake cycle, feeding, 
etc. (27). Optogenetics has also helped to link dysfunctions of 
specific neurocircuitry or neural ensembles with negative emo-
tions and psychiatric conditions, such as fear, anxiety, depression, 
and addiction (28, 29). It is envisioned that future refinement of 
optogenetic techniques will open the possibility to use light to 
treat neurological and psychiatric conditions (23).
FUtUre StepS in 
pSychOpharMacOlOGy
Breakthrough of genetics and molecular biology in psychop-
harmacology contributed enormously to understanding the 
etiopathological basis of mental illness and helped to identify 
several new targets for drug development. Nevertheless, it has 
been disappointing to observe that despite these advancements, 
successful introductions of new medications into clinical practice 
remain very modest.
Major pharmaceutical companies are currently disengaging 
from research and drug-discovery programs in psychiatry, and 
over the last 10 years, very few new products have seen the market 
(19, 30). Most of the treatments currently available remain or are 
derived from those agents introduced by serendipitous discover-
ies during the mid 50s; the magic years of psychopharmacology. 
Whereas very few innovative biological mechanisms identified 
over the last 30 years have been successfully targeted with new 
medications. The reasons for this lack of success are multiple. 
On the one hand, development of CNS drugs is intrinsically 
complicated, and compared to the treatment of other disease 
areas, success rates remain low. Moreover, for neuropsychiatric 
drugs, the stringent requirements imposed by regulatory agen-
cies represent a disincentive for pharmaceutical industries. 
Paradoxically, a third reason hampering drug development in 
neuropsychiatry is the attraction that molecular biology and 
genetics had for basic scientists. This shift of interest has drawn 
researchers’ interests toward these new disciplines draining 
human and financial resources from classical neuropsychop-
harmacology. Genetic and molecular biology techniques 
progressively replaced classical pharmacological approaches 
to probe the validity of biological targets or to test new disease 
etiopathological mechanisms. There is general optimism that 
introduction of these new approaches will help to advance our 
knowledge in psychiatry and to develop more efficacious treat-
ments in the long run. In the short term, reduction of interest in 
using pharmacological tools to investigate biomedical questions 
is reducing the cross-fertilization between basic science and 
applied research in pharmaceutical industry.
Actions should be taken to engage basic science and pharma-
ceutical industry in a common effort to increase the chances of 
successful development of new medications. The development 
of a clear and well-structured translational approach for medi-
cation development is a major challenge in CNS drug develop-
ment. From the preclinical standpoint, it is essential to develop 
better animal models to mimic the complex traits typical of 
psychiatric conditions. At the clinical level, when possible, it 
is important to deconstruct psychiatric categories into identifi-
able endophenotypes and to cluster patients into populations 
as homogeneous as possible (31). In addition, it is important to 
have biomarkers or surrogate markers that can be determined 
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in laboratory animals and in humans. Finally, pharmacological 
manipulations should be used in conjunction with molecular 
and genetic approaches.
Gender difference in psychopharmacology is another aspect 
that needs attention. In 1993, the FDA issued its Guideline for 
the Study and Evaluation of Gender Differences in the Clinical 
Evaluation of Drugs. From the publication of this document, the 
inclusion of female subject in clinical trials increased progres-
sively. Nevertheless, preclinical research is still based on animal 
models originally developed using males. Traditionally, males 
are preferred to females to avoid potential confounding factors 
linked, for example, to hormonal fluctuations associated with 
the estrus cycle. The perception is that these fluctuations can 
influence behavior, decrease the homogeneity of results, and 
enhance the variability in response to drugs (32). It is short-
sighted to ignore women who represent more than half of the 
population at global level, who use such medications at higher 
rate, and who show differences from males in etiopathology 
and prevalence. For instance, it is well known that mental ill-
nesses, such as depression, anxiety, eating disorders, and post-
traumatic stress disorder, show higher prevalence in females, 
whereas alcohol abuse and antisocial personalities predominate 
in males (33, 34).
Male and female also differ in drug response due to several 
pharmacokinetic (PK) and pharmacodynamic (PD) factors (35). 
Hence, inclusion of females in preclinical tests is important to 
better determine the PK/PD parameters predictive of drug 
response in clinical populations. The Zolpidem case provides a 
prototypical example of sex-related difference in response to a 
drug. This hypnotic compound is subjected to a lower metabolic 
elimination rate in females compared to males. This has inspired 
a historical decision by FDA in 2013 to cut the recommended 
therapeutic dose in half for women. This is the first example ever 
of an approved medication explicitly taking into account gender-
related differences in drug response. Establishment of gender 
oriented policies in drug development is now a priority, and more 
is expected in the near future.
Notably, neuroscience is a discipline in which male bias 
in preclinical research is the norm (36). This gap needs to be 
filled, and better animal models are needed, taking into account 
sex-related differences in behavior and in response to drugs. 
Awareness that gender differences exist in neuropsychiatric 
disease, etiopathology, and in response to treatment intervention 
is critical to enhance more efficacious and safer medications for 
mental illness.
Exploration of disease etiopathology and identification of 
new targets amenable to drug development including genetic, 
epigenetic, brain imaging, proteomics, and behavioral and 
pharmacological data should occur altogether. The need to build 
large databases containing all this information is pressing. The 
computational and the statistical tools to acquire “big data” in 
biomedical science are now becoming available and are relatively 
user friendly. If made open source these databases would be 
of inestimable value for investigators involved in basic science 
as well as in applied research. There are several advantages in 
making scientific data open. For research teams, data sharing is 
a unique opportunity to synergize and enhance the possibility 
to successfully achieve ambitious scientific discoveries. It is a 
cost-effective strategy, especially when expensive technologies 
are applied to generate the data. Moreover, for those investiga-
tors that do not have access to expensive technologies, open 
data enable the possibility to indirectly benefit from them. This 
can be a unique instrument to help cultivating high quality 
research also in those countries that do not or cannot invest 
enough money in expensive technologies. Ultimately, open data 
programs can help to raise the research impact at global level 
thus helping to fill the gap between high and low developed 
countries. Open data also help to evaluate the quality of the 
research, contribute to prevent its duplication, and promote 
reproducibility.
In the promotion of open data policies, there are also 
obstacles to surmount. These include issues arising from 
intellectual property rights and the inclination of researchers 
to protect their data. Nevertheless, data sharing approaches 
have proven successful with the Human Genome Project, 
and there is a lot of expectation from the Brain initiative 
and the European Human Brain project. Learning from these 
experiences provides a substantial help to advance the field 
of psychopharmacology.
Our understanding of brain function, cognition, emotion, and 
mental illness is advancing rapidly. In a common effort, basic 
and applied preclinical and clinical research should concentrate 
energy toward the validation of new pharmacological targets and 
improve the success rate in drug development in psychiatry.
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